NCT00006054: Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies |
|
|
| Terminated | N/A | | US | anti-thymocyte globulin, busulfan, cyclophosphamide, cyclosporine, etoposide, methotrexate, methylprednisolone, prednisone, Allogeneic Bone Marrow Transplantation | Fairview University Medical Center | Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome, Familial Erythrophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, X-linked Agammaglobulinemia, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Hyper IgM Syndrome, Severe Combined Immunodeficiency, Leukocyte Adhesion Deficiency Syndrome, Virus-Associated Hemophagocytic Syndrome | 12/02 | 12/02 | | |
NCT00834496: Switching From One Type of Anti-rejection Drug (Tacrolimus or Cyclosporine) to Another (Sirolimus) Approximately 90-180 Days After Liver Transplantation |
|
|
| Withdrawn | N/A | 0 | US | Liver biopsy | Thomas Jefferson University, Wyeth is now a wholly owned subsidiary of Pfizer | Side Effects of Calcineurin Inhibitors, Renal Toxicity, Hepatic Fibrosis on Biopsy, Neurotoxicity, Post Transplant Diabetes | 01/10 | 01/10 | | |